Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood's Ark Invest purchased shares of CoreWeave (CRWV), Scribe Therapeutics (SCTX), and Freenome (FRNM), all trading 28% to 57% below their highs. CoreWeave saw 113% revenue growth but remains unprofitable. Scribe Therapeutics focuses on gene silencing and has cash until 2029. Freenome gained FDA approvals for cancer screening tests and rose 7% post-purchase.
How this was made
The 30-second read
Why it matters
The purchases provide a fresh, albeit modest, catalyst for each ticker, but the overall market impact remains limited.
Market read
Ark's new positions may spark short‑term buying interest but are unlikely to move broader indices.
What to watch
CoreWeave's high leverage and Freenome's reliance on FDA approvals introduce significant downside risk.
Background
Ark Invest's weekly buying spree adds to three high‑volatility growth stocks that have recently underperformed.
Ticker impact
Ark Invest added to its stake in CoreWeave, a company whose shares have fallen 28%‑57% and are near 52‑week lows.
likely modest upside as the market prices in Ark's confidence
Ark's purchase is a new, small‑scale catalyst but the company remains loss‑making and highly leveraged.
Ark Invest increased its holding in Scribe Therapeutics, a clinical‑stage gene‑editing firm whose shares have dropped sharply.
possible slight upward pressure, limited by cash‑burn concerns
The purchase is fresh news but the company faces significant execution risk.
Ark Invest bought Freenome shares, which rose 7% on the day of the purchase but remain down ~30% from recent highs.
likely continued modest upside as the market digests FDA clearances and Ark backing
Freenome has recent FDA approvals and a high‑profile investor, providing a fresh catalyst.
Market effects
Highlights continued interest in AI and biotech stocks despite recent price declines.
U.S. growth‑oriented investors may allocate more capital to AI compute and early‑stage biotech.
Limited to U.S. listed growth stocks; no broader macro impact.
Counterpoint
Ark's purchases could be a contrarian bet on distressed growth stocks that may underperform further.
Key entities
- InvestorCathie Wood
Co‑founder, CEO, and CIO of Ark Invest.
- CompanyCoreWeave
AI compute provider with significant loss profile.
- CompanyScribe Therapeutics
Clinical‑stage epigenetic therapy developer.
- CompanyFreenome
Blood‑based early cancer detection platform.
